iCAD, Inc.

Equities

ICAD

US44934S2068

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
1.56 ^USD	+2.63%		-2.50%	-11.86%

Apr. 11	ICAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium	CI
Apr. 09	ICAD, Inc. and Densitas, Inc. Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation	CI

ICAD to Participate at the Imagine AI + Healthcare Investor Summit

December 06, 2021 at 01:39 pm EST

NASHUA, N.H., Dec. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens, President and incoming Chief Executive Officer, will present a corporate overview at Oppenheimer’s Imagine AI + Healthcare Investor Summit being hosted by Oppenheimer in partnership with the Alliance for AI in Healthcare (AAIH).

Oppenheimer’s Imagine AI + Healthcare Investor Summit
Date: Tuesday, December 7^th
Time: 11:00 a.m. to 11:20 a.m. ET
Registration Link

About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

Contact:
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com

Investor Relations:
Brian Ritchie, LifeSci Advisors
+ 1-212-915-2578
britchie@lifesciadvisors.com

Latest news about iCAD, Inc.

ICAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium	Apr. 11	CI
ICAD, Inc. and Densitas, Inc. Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation	Apr. 09	CI
ICAD, Inc. Announces Commercial Availability of ProFound Cloud	Apr. 02	CI
Transcript : ICAD, Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
Earnings Flash (ICAD) ICAD Posts Q4 Revenue $4.7M, vs. Street Est of $4.3M	Mar. 12	MT
ICAD, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 12	CI
ICad to Present Three Mammography Studies at Radiology Conference; Shares Rise	Feb. 28	MT
ICAD, Inc. Appoints Hedvig Hricak to the Board of Directors	Feb. 26	CI
ICAD, Inc. Appoints Michael John Doyle to its Board of Directors	Jan. 25	CI
Icade Appoints New CFO	Jan. 11	MT
ICAD, Inc. Expands Executive Sales Leadership Team as Business Grows	Dec. 18	CI
ICAD, Inc. AI-Powered Solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare	Nov. 28	CI
ICAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite	Nov. 27	CI
Icade Closes Divestment of Grand Central Building in France	Nov. 24	MT
ICAD Partners With CancerIQ to Expand Breast Healthcare Service	Nov. 20	MT
RTX's Collin Aerospace Unit Wins Services Contract for Saudi Arabia's NEOM Bay Airport	Nov. 15	MT
Transcript : ICAD, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Earnings Flash (ICAD) ICAD Posts Q3 Revenue $4.1M, vs. Street Est of $5.91M	Nov. 13	MT
ICAD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
ICAD, Inc. Announces Resignation of Michael Klein as Member of the Board	Nov. 07	CI
Elekta Enters $5.5 Million Deal to Acquire iCAD's Xoft Business	23-10-23	MT
Elekta AB (OM:EKTA B) acquired Xoft, Inc. from iCAD, Inc. for $5.8 million.	23-10-22	CI
ICAD, Inc.(NasdaqCM:ICAD) dropped from S&P Global BMI Index	23-09-18	CI
Health Canada Grants Device License for iCAD's Profound Risk 2.0, Revolutionizing Breast Cancer Risk Via A 1-2 Year Assessment	23-08-16	CI
Transcript : ICAD, Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14

Chart iCAD, Inc.

Duration

Period

More charts

Company Profile

iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Companyâs Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for iCAD, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.56 USD

Average target price

4.833 USD

Spread / Average Target

+209.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
ICAD, INC.	-11.86%	41.11M
THERMO FISHER SCIENTIFIC	+8.35%	219B
DANAHER CORPORATION	+9.41%	187B
INTUITIVE SURGICAL, INC.	+11.75%	134B
BOSTON SCIENTIFIC CORPORATION	+19.34%	101B
SIEMENS HEALTHINEERS AG	+0.76%	62.27B
EDWARDS LIFESCIENCES CORPORATION	+15.08%	52.82B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-2.10%	47.49B
AGILENT TECHNOLOGIES, INC.	+0.10%	40.79B
GE HEALTHCARE TECHNOLOGIES INC.	+11.50%	39.35B

Other Advanced Medical Equipment & Technology